Financial Data and Key Metrics Changes - Relmada closed 2025 with a cash balance of $93 million, an increase from approximately $45 million at the end of 2024, primarily due to a successful $160 million private financing [19][20] - Research and development expenses for Q4 2025 totaled $8.1 million, a decrease from $11 million in Q4 2024, driven by reduced study costs from completed trials [20] - General and administrative expenses increased to $12.3 million in Q4 2025 from $8.1 million in Q4 2024, primarily due to higher compensation costs [21] - The net loss for Q4 2025 was $19.9 million, or $0.27 per share, compared to a net loss of $18.7 million, or $0.62 per share, in Q4 2024 [23] Business Line Data and Key Metrics Changes - The NDV-01 program reported a 12-month complete response rate of 76% in high-risk NMIBC patients, with an 80% response rate in the BCG unresponsive population [11][12] - Sepranolone is preparing for a proof of concept study in Prader-Willi syndrome, with plans to initiate in mid-2026 [18] Market Data and Key Metrics Changes - The U.S. market for intermediate-risk bladder cancer patients is estimated at 70,000-75,000 annually, while the second-line treatment for BCG unresponsive patients is about 5,000 annually [13][15] - Only 35% of intermediate-risk patients currently receive adjuvant therapy, indicating significant market potential for new treatments [53] Company Strategy and Development Direction - The company plans to initiate the phase 3 RESCUE program for NDV-01 in mid-2026, with two registrational pathways focusing on intermediate-risk and BCG unresponsive patients [5][13] - The strategic focus includes enhancing clinical data presentation and establishing a robust supply chain for sepranolone [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical programs and long-term prospects, emphasizing the importance of execution in the upcoming RESCUE program [24][57] - The company aims to redefine the standard of care in bladder cancer with NDV-01, leveraging its unique sustained-release formulation [17] Other Important Information - The company has strengthened its development team with the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Urology [6] - A successful $160 million private financing was completed, providing capital through 2029 [8][20] Q&A Session Summary Question: Will additional data from the phase two study be presented? - Management confirmed that updated 12-month data will be presented at AUA and plans to share data every three months [26][29] Question: How will the company ensure that second-line patients are accurately categorized? - The company will limit prior therapy lines to two and will monitor patient characteristics closely to ensure accurate categorization [27][30] Question: What is the expectation for enrollment cadence across the studies? - Management indicated that the unique in-office profile of NDV-01 could serve as a recruitment advantage, despite a crowded market [34][35] Question: What is the FDA's requirement for follow-up duration before submitting the NDA? - The FDA has not stipulated a minimum follow-up duration but is interested in the totality of the data regarding response and durability [36] Question: How do the complete response rates compare between phase 2 and phase 3? - Management expects to exceed the benchmark of 75% two-year recurrence-free survival based on the statistics structured for the trial [42]

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of ZUSDURI and increased sales of JELMYTO [19][20] - The net loss for the year was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - ZUSDURI generated $15.8 million in revenue for 2025, reflecting early launch dynamics [5][14] - JELMYTO generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [7][17] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care with 102 unique prescribers and 32 repeat prescribers for ZUSDURI [15] - Over 95% of covered lives had open access to ZUSDURI by year-end 2025 [15] Company Strategy and Development Direction - The company’s top priority is the commercial launch of ZUSDURI, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5][7] - The company is advancing its pipeline with UGN-103 and UGN-104, with plans to submit an NDA for UGN-103 in the second half of 2026 [8][12] - A refinancing of the debt facility with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early trajectory of ZUSDURI's launch and noted that the permanent J-code has facilitated more predictable patient access [5][6] - The company anticipates that the conversion timeline from patient enrollment forms to dosing will narrow as sites gain familiarity with the product [16] - Management is optimistic about the potential for ZUSDURI and its pipeline products to create long-term value for patients and shareholders [9][23] Other Important Information - The company expects JELMYTO net product revenues for 2026 to be in the range of $97 million to $101 million, reflecting a year-over-year growth rate of approximately 3% to 7% [23] - Full-year 2026 operating expenses are expected to be in the range of $240 million to $250 million, driven by increased sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for ZUSDURI - Management indicated that they would consider providing formal guidance for ZUSDURI after gaining visibility into steady-state demand, approximately two quarters post the permanent J-code [29] - The number of patient enrollment forms has increased since the permanent J-code became effective, with new and repeat prescribers contributing to this growth [31][32] Question: Trends in repeat prescribers and their likelihood of becoming repeat prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement and repeat prescribing [39] Question: Timing for UGN-103 market introduction and its commercial positioning - UGN-103 is expected to be introduced after obtaining a permanent J-code, with a potential launch in early 2028 [41] Question: Current use of ZUSDURI among patients and expected shifts in use patterns - ZUSDURI is being used primarily for patients who recur early, have frequent recurrences, or are unfit for surgery, with expectations for increased utilization as community practices gain experience [48][49] Question: Opportunities for ZUSDURI in the adjuvant setting - There is enthusiasm for expanding UGN-103 into the adjuvant setting for new diagnoses, with ongoing discussions about potential combinations with other agents [60][61]

Core Viewpoint - enGene Holdings Inc. is experiencing a significant increase in stock price following the release of preliminary data from its Phase 2 LEGEND trial for detalimogene voraplasmid in high-risk bladder cancer patients [2][6]. Group 1: Trial Data and Results - The LEGEND trial included 99 patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [2]. - Preliminary analysis showed a 63% complete response (CR) rate at any time for 62 patients, with a 56% CR rate at 3 months and a 62% CR rate at 6 months for 37 patients [8]. - The company exceeded its enrollment target by 25%, completing enrollment of 125 patients in the pivotal cohort [3][4]. Group 2: Future Plans and Expectations - The company plans to file a Biologics License Application (BLA) in the second half of 2026, with potential FDA approval expected in 2027 [5][6]. - enGene anticipates providing a data update on the LEGEND trial's pivotal cohort in the second half of 2026 [5]. Group 3: Market Performance - enGene Holdings shares rose by 64.73% to $9.90, reaching a new 52-week high [6].

Summary of Relmada Therapeutics Conference Call Company Overview - **Company Name**: Relmada Therapeutics - **Ticker Symbol**: RLMD - **Public Listing**: NASDAQ since 2019, public since 2014 - **Focus Area**: Central nervous system and oncology, specifically bladder cancer treatment [2][3] Key Developments - **Strategic Shift**: The company has adopted a new strategy to lower risk while maintaining upside potential, leading to the acquisition of two programs [3] - **NDB-01**: The most advanced program, focusing on non-muscle invasive bladder cancer, which constitutes about 75% of bladder cancer cases [4][5] - **Sopranolol**: An early-stage program for treating compulsive disorders, with potential applications in Tourette's syndrome and Prader-Willi syndrome [25][26] Bladder Cancer Insights - **Prevalence**: Bladder cancer accounts for 1 in 25 cancers in the U.S., with approximately 70,000 to 80,000 new cases annually [5][6] - **Patient Demographics**: Primarily affects older men, with an average disease duration of around 10 years [5] - **Recurrence Rate**: High recurrence, with 50% of patients experiencing recurrence within one year and 70-80% within two years [6] Treatment Landscape - **Current Treatments**: Include surgery (TURBT), BCG immunotherapy, and chemotherapy [7][9] - **Challenges with BCG**: BCG is difficult to tolerate and has been in shortage for several years [9] - **Emerging Chemotherapy**: The combination of gemcitabine and docetaxel (referred to as Gendoza) is effective but has limitations in administration and preparation [12][13] NDB-01 Advantages - **Delivery Method**: NDB-01 is an extended-release gel that allows for easier administration of chemotherapy directly in the bladder [14][15] - **Efficacy**: Early data shows a 90% cancer-free rate at six months in the ongoing phase 2 study [19][20] - **Market Position**: Competes with products from Johnson & Johnson and UroGen, which have higher treatment costs [21][22][23] Financial Overview - **Cash Position**: As of the end of Q2, the company had $20.6 million in cash and equivalents [28] - **Share Structure**: 33.2 million shares outstanding, indicating a clean balance sheet [28] - **Future Financing**: The company acknowledges the need for future financing to support clinical trials but does not anticipate immediate needs [41] Market Potential - **Treatment Costs**: UroGen's treatment costs $21,000 per treatment, while Johnson & Johnson's is $69,000, indicating a significant market opportunity for NDB-01 [22][23] - **Annual Procedures**: There are approximately 100,000 surgeries annually for non-muscle invasive bladder cancer in the U.S., suggesting substantial revenue potential [23] Conclusion - **Regulatory Path**: Plans to discuss with the FDA in Q4 and aim to start registration studies in Q2 2026 [24] - **Insider Confidence**: Recent insider buying by executives indicates confidence in the company's future [45][46] This summary encapsulates the key points from the Relmada Therapeutics conference call, highlighting the company's strategic direction, product developments, market landscape, and financial positioning.

Financial Data and Key Metrics Changes - UroGen Pharma reported net product revenues of $24.2 million for the second quarter of 2025, an 11% increase compared to $21.8 million in the same period in 2024, driven by underlying demand growth of 7% and price favorability [9][30] - The net loss for the second quarter of 2025 was $49.9 million, or $1.5 per basic and diluted share, compared to a net loss of $33.4 million, or $0.82 per basic and diluted share in the same period in 2024 [32][33] - Cash, cash equivalents, and marketable securities totaled $161.6 million as of June 30, 2025, providing sufficient capital for the launch of Zysturi and support for the pipeline [12][33] Business Line Data and Key Metrics Changes - Jelmyto continues to show strong growth with net product revenues of $24.2 million, reflecting continued adoption and usage among urologists [9][30] - Zysturi, the newly approved product, is expected to penetrate a total available market exceeding $5 billion annually, with an expanded sales team of 82 territories as of August 1, up from 50 previously [7][8] Market Data and Key Metrics Changes - The total available market for Zysturi is estimated to exceed $5 billion annually, indicating a significant opportunity for UroGen Pharma as it transitions from a rare disease-focused company to a multi-product organization [7][8] - Approximately 59,000 annual patients in the US face recurrence of low-grade, intermediate-risk, non-muscle invasive bladder cancer, highlighting the unmet medical need that Zysturi addresses [6] Company Strategy and Development Direction - UroGen Pharma aims to develop and commercialize a differentiated portfolio of treatments addressing unmet needs across urothelial and specialty cancers, with Zysturi being a primary growth driver [4][10] - The company is focused on a disciplined strategic launch of Zysturi, leveraging learnings from the launch of Jelmyto to ensure a successful market entry [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the launch of Zysturi, noting strong interest from healthcare providers and the potential for significant patient uptake once a permanent J code is assigned [41][42] - The company anticipates broader reimbursement and market access in 2026, which is expected to significantly enhance adoption rates [28][34] Other Important Information - The phase three Utopia trial for UGN-103 is fully enrolled, with initial complete response data expected by the end of 2025, which will be shared with the FDA to inform the regulatory path forward [11][21] - UroGen's long-term goal includes expanding its product portfolio while driving commercial success and profitability [12][33] Q&A Session Summary Question: Metrics for July regarding Zysturi launch - Management indicated that it is still early to provide specific metrics but noted positive receptivity from healthcare providers and a strong interest in the new treatment option [36][39] Question: Reimbursement process for Zysturi - The reimbursement process is currently manual due to the miscellaneous J code, and while it is too early to report paid claims, practices are being educated on the claims process [49][54] Question: Comparison of Zysturi launch to Jelmyto - Management noted that while there are similarities in the launch process, the demographic for Zysturi is much larger, allowing for potentially quicker adoption compared to Jelmyto [57][58] Question: Utopia trial and FDA discussions - Management has not yet interacted with the FDA regarding the Utopia trial but expects to do so once sufficient data is available [60][62] Question: Expansion of prescribers post-J code assignment - Management indicated that they will expand outreach beyond the initial 2,000 identified prescribers once the permanent J code is assigned, targeting a broader segment of the urology market [74][78] Question: Impact of Zysturi on Jelmyto sales - It is too early to determine if Zysturi's launch will have a positive impact on Jelmyto sales, but management believes that increased market presence will support steady growth for Jelmyto [78][79]

Summary of Aura Biosciences (AURA) FY Conference Call Company Overview - Aura Biosciences is focused on ocular oncology, with a late-stage asset in Phase III clinical development for ocular melanoma, which is identified as the key value driver for the company [2][3] - The company has multiple clinical data readouts expected in the ocular oncology therapeutic area, including the COMPASS study, which is anticipated to complete enrollment this year and provide top-line data potentially in late 2026 or early 2027 [3][4] Key Opportunities - The ocular melanoma market has an estimated potential of 66,000 patients, with three synergistic indications that allow for orphan pricing and rare disease opportunities [4] - The bladder cancer program has recently initiated a Phase II study, with a new formulation designed to differentiate between ocular and bladder cancer treatments [5] Clinical Trial Insights - The bladder cancer Phase I trial is designed as a "window of opportunity" study, allowing for quick assessment of feasibility and early efficacy signals, although it does not measure durability of response [6][7] - Initial data from the bladder cancer study showed a remarkable complete response rate of approximately 80% in the intermediate-risk population with a single dose [8] - Biomarker data indicated strong immune activation, suggesting potential for long-term adaptive immunity [9][10] Safety and Efficacy - The treatment has shown a favorable safety profile, with only grade one adverse events reported, indicating a well-tolerated drug that can be administered quickly in an office setting without general anesthesia [11][12] - The ongoing Phase I/II trial aims to evaluate durability of response, with initial data expected by the end of 2025 and comprehensive data by the end of 2026 [17][18] Market Potential - The bladder cancer market is estimated to have around 80,000 patients in the U.S. for intermediate-risk cases, with a significant opportunity for a safe drug that can be administered in an office setting [23] - The company also sees potential in the high-risk bladder cancer market, addressing the unmet need for durability of response [24] Choroidal Melanoma Insights - The Phase II data for choroidal melanoma showed 80% tumor control and 90% visual acuity preservation at twelve months, indicating a strong safety and efficacy profile [25][26] - The pivotal trial design includes a randomized, sham-controlled study, which has received SPA agreement from the FDA, enhancing the likelihood of approval [27][29] Pricing Strategy - Aura Biosciences is considering orphan disease pricing, with benchmarks from successful drugs in the ultra-rare space, potentially leading to a multibillion-dollar franchise [43][44] - The company aims to position its drug as a safe alternative that prevents blindness, which carries a high value proposition for pricing discussions with payers [45] Future Directions - The ongoing Phase II study for choroidal metastases is expected to provide proof of concept data by the end of the year, with a broader inclusion criteria to enhance the study's applicability [49][50] - The company is optimistic about the potential of its drug beyond ocular oncology, indicating a broader market opportunity across various tumor types [51] Conclusion - Aura Biosciences is strategically positioned in the ocular oncology market with promising clinical data and a robust pipeline, focusing on safety, efficacy, and market potential to create shareholder value in the coming years [42]

Core Insights - Johnson & Johnson announced promising results from the Phase 2b SunRISe-1 study of TAR-200, showing over 82% of patients achieved complete response (CR) and more than half remained cancer-free for at least one year [1][4] - TAR-200 is positioned as a transformative treatment for patients with BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly those ineligible for radical cystectomy [1][8] Company Overview - Johnson & Johnson is focused on healthcare innovation, aiming to provide less invasive and more effective treatment options for complex diseases [9] - The company has initiated a new drug application with the FDA for TAR-200 under the Real-Time Oncology Review program, following its Breakthrough Therapy Designation [6][4] Study Details - The SunRISe-1 study enrolled 85 patients, with a complete response rate of 82.4% and a median duration of response of 25.8 months [1][7] - The study specifically targets patients with carcinoma in situ, with or without papillary disease, who have not responded to BCG therapy [7] Treatment Efficacy - The treatment demonstrated a high level of sustained disease control, with 52.9% of responders maintaining CR at one year and 86.6% remaining cystectomy-free [1][2] - Most treatment-related adverse events were mild, with only 3.5% of patients discontinuing treatment due to adverse effects [2] Market Context - Bladder cancer is among the ten most common cancers globally, with limited treatment options available for patients who do not respond to initial BCG therapy [1][8] - High-risk non-muscle invasive bladder cancer accounts for 15-44% of NMIBC cases, characterized by high-grade tumors and a tendency to recur [8]